secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0000950170-25-073950
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum extends $20M Pfizer milestone payment to Oct 2029; interest rises to 10%
-------------------------------------------------------------------------------

- $20M regulatory milestone due Oct 2026 extended to Oct 2029 via amended promissory note.
- Interest rate increases from 8% to 10%, compounded daily, starting Oct 26, 2026.
- ITIL pays Pfizer a transaction fee plus legal expenses; no senior debt or liens without Pfizer consent.
- CEO says extension allows capital to be invested in ORLYNVAH launch and geographic expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025073950/0000950170-25-073950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025073950/itrm-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-073950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer